Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp
复制标题
蛋白酶体抑制剂MG132通过增强细胞凋亡和抑制P-gp逆转胃癌多药耐药
DOI:
10.4161/cbt.7.4.5483
复制
发表时间:
2008-04
影响因子:
3.6
通讯作者:
Zhang, Yafei
中科院分区:
文献类型:
--
作者:
Wu, Kaichun;Xia, Lin;Zhai, Huihong;Li, Xiaohua;Chen, Bei;Luo, Guanhong;Du, Wenqi;Shi, Yongquan;Du, Rui;Fan, Daiming;Zhang, Yafei
ABSTRACT Multidrug resistance (MDR) is a major impediment to the effective chemotherapy of many human malignancies. Although much effort has been devoted to develop new drugs for overcoming MDR, until now, still no useful method of reversing MDR, suitable for clinical use, has emerged from this large quantity of work. Some researchers have reported that proteasome inhibitors could induce apoptosis in a variety of cancer cells. In the present study, we found that, in vincristine-resistant human gastric cancer cell line SGC7901/VCR, proteasome inhibitor MG132 was an effective inducer of apoptosis, and also had the capacity of downregulating the expression of anti-apoptotic Bcl-2 and MDR1 (P-gp), by which MG132 resensitized tumor cells to the apoptosis induced by anticancer drugs. Data presented by drug sensitivity assay further demonstrated that MG132 could reverse the resistant phenotype of gastric cancer cells effectively through both enhancing drug-induced apoptosis and inhibiting P-gp. The further study of the effectiveness and safety of proteasome inhibitor in vivo may be helpful for developing a new possible strategy to treat gastric cancer MDR.
登录
查看更多内容
影响因子:
3.3
作者:
P. Richardson;C. Mitsiades
通讯作者:
P. Richardson;C. Mitsiades
影响因子:
3.3
作者:
K. Tobinai
通讯作者:
K. Tobinai
DOI:
10.1111/j.1440-1746.2005.03797.x
发表时间:
2005-03-01
影响因子:
4.1
作者:
Fan, DM;Zhang, XY;Wu, KC
通讯作者:
Wu, KC
影响因子:
3.5
作者:
Wu, HM;Chi, KH;Lin, WW
通讯作者:
Lin, WW
影响因子:
6.5
作者:
Masdehors, P;Omura, S;Delic, J
通讯作者:
Delic, J